

The Combinatorial Approach to Asymmetric Hydrogenation.

Johannes G. de Vries

DSM Pharma Chemicals
and
University of Groningen

IASOC 2004, Ischia

1. DSM. A century of changes.
2. Homogeneous catalysis for fine chemicals
3. HTE approach; ligand libraries
4. MonoPhosTM ligands for asymmetric hydrogenation
5. Instant Ligand Libraries
6. Mechanism
7. The wedding between homogeneous catalysis & biocatalysis


DSM Pharma Chemicals

Unlimited. **DSM**



The specialty company

**Life science products
Polymeric materials
Industrial Chemicals**




DSM Pharma Chemicals

Unlimited. **DSM**

Strategic impact Petrochem & Roche deals

4



Total sales ~ € 7 bn
Specialties from ~ 50% to > 80%

DSM Pharma Chemicals

Unlimited. **DSM**

Homogeneous Catalysis for Fine Chemicals

5

Important technologies

- Asymmetric hydrogenation (olefins, ketones, imines, enamides)
- Asymmetric transfer hydrogenation (ketones)
- Asymmetric epoxidation
- Aromatic substitution
 - Heck
 - Suzuki/Negishi
 - Sonogashira
 - Amination
 - Cyanation
- CO chemistry (hydroformylation, carbonylation, amidocarbonylation)
- Isomerisation and racemisation
- Oxidation
 - benzylic and allylic oxidation
 - alcohols to aldehydes or acids
 - olefins to epoxides

DSM Pharma Chemicals

Unlimited. **DSM**

Asymmetric Hydrogenation

6

- Nobel prize winning chemistry
- Several hundred ligands known
- Many thousands examples on lab-scale

Till about 5 years ago the use of this technology for the production of fine chemicals was scarce.

Why?

Reviews

H.U. Blaser, F. Spindler and M. Studer, *Appl. Catal.: A General*, **2001**, 221, 119.

J.G. de Vries in *Encyclopedia of Catalysis*, I. Horvath, ed. **2003**, Vol 3, p 295.

DSM Pharma Chemicals

Unlimited. **DSM**

1. Time to market constraints in pharmaceuticals production leads to very short development time
2. Competing technologies
3. Cost
 - Cost of metal (Rh or Ru)
 - Cost of ligand
 - Activity of the catalyst.
 - Stability of the catalyst
 - Recovery or recyclability
4. Availability of catalysts on short notice
5. Patents and high cost of licensing
6. Reliability, real or perceived

DSM Pharma Chemicals

Unlimited. **DSM**

Combinatorial / HTE approach to asymmetric hydrogenation

Goal: Find catalytic solution for customer requests within 3 weeks


Requirements:

- *Hardware*
 - Endeavor (8 high pressure reactors)
 - Two proprietary reactors for high pressure (96 and 28 vessels)
- *HTE Analysis*
 - GC
 - HPLC (including chiral HPLC)
 - Flow-NMR
- *Libraries of ligands*

Review: J.G. de Vries and A.H.M. de Vries, *Eur. J. Org. Chem.*, **2003**, 799-811.

Review Ligand libraries: C. Gennari, U. Piarulli, *Chem. Rev.* **2003**, 103, 3071.

- Libraries of phosphine ligands are not easy to prepare.
- Phosphoramidites on the contrary are easily prepared in 2 steps:




- Diversity from both diol and amine part.
- Chirality from BINOL or TADDOL skeleton or chiral amine.
- Very successful in copper catalysed asymmetric 1,4 addition of Et_2Zn to cyclic enones (B. Feringa et al, RUG)
- Not known for asymmetric hydrogenation!

DSM Pharma Chemicals

Unlimited. **DSM**

Easy synthesis of phosphoramidites

10





DSM Pharma Chemicals

Unlimited. **DSM**

Strong solvent effect but highly enantioselective!

11




Entry	Solvent	Temp	e.e.
1.	CH ₃ OH	RT	70%
2.	CH ₂ Cl ₂	RT	95%
3.	CH ₂ Cl ₂	5°C	97%
4.	THF	RT	93%
5.	Acetone	RT	92%
6.	PrOCH ₂ CH ₂ OH	RT	77%

DSM Pharma Chemicals

Unlimited. **DSM**

Asymmetric hydrogenations with MonoPhos™

12




Entry	R	R'	Solvent	e.e. (RT)	e.e. (0°C)
1.	Ph	Me	CH ₂ Cl ₂	95%	97%
2.	Ph	H	EtOAc	97%	
3.	H	Me	EtOAc		>99%
4.	H	H	EtOAc	>99%	

M. van den Berg, A.J. Minnaard, E.P. Schudde, J. van Esch, A.H.M. de Vries, J.G. de Vries and B.L. Feringa, *J. Am. Chem. Soc.*, **2000**, 122, 11539.

WO 02/04466

DSM Pharma Chemicals

Unlimited. **DSM**



	R	R	Solvent	e.e. (RT)	e.e. (0 °C)
1.	H	Me	CH ₂ Cl ₂	95%	97%
2.	3-MeO	H	CH ₂ Cl ₂	97%	
3.	4- Ph	Me	CH ₂ Cl ₂	95%	
4.	4-OAc, 3-OMe	Me	EtOAc	94%	98%
5.	4-Ac	Me	CH ₂ Cl ₂	99%	

M. van den Berg *et al.*, *Adv. Synth. Catal.* **2003**, 345, 308-322.

DSM Pharma Chemicals

Unlimited. **DSM**


Advantages of MonoPhos™ hydrogenations

14

- MonoPhos can be prepared in a single step from commercially available BINOL (Compare with DUPHOS: 6 steps).
- MonoPhos is an order of magnitude cheaper than currently available bisphosphines.
- The hydrogenation rate can be increased by increasing the H₂ pressure *without loss in enantioselectivity!*
- At S/C ratio of 2000 full conversion in 2 h at 10 bar.
- Method of choice for asymmetric olefin hydrogenation.
- Large library of ligands available.

DSM Pharma Chemicals

Unlimited. **DSM**




H. Bernsmann *et al.*, submitted to JOC

DSM Pharma Chemicals

Unlimited. **DSM**


β -Amino Acids by Asymmetric Hydrogenation



- Synthesis of precursors: *Z/E* mixtures with predominantly *Z*
 - Asymmetric hydrogenation of *E* is facile.
 - Asymmetric hydrogenation of *Z* is difficult. For *R* = aryl so far only a few successful catalyst systems known: Ru-BINAPO, Tangphos (X. Zhang *et al.*)
 - Two strategies can be developed:
 - find good ligand for *Z*
 - synthesis of only *E*
- (See: D. Heller *et al.* *Angew. Chem. Int. Ed.* **2003**, 42, 913)

DSM Pharma Chemicals

Unlimited. **DSM**




Substrate	Ligand	Solvent	e.e.
<i>E</i> - R = CH ₃	MonoPhos	CH ₂ Cl ₂	95%
<i>E</i> - R = CH ₃	1	CH ₂ Cl ₂	99%
<i>Z</i> - R = CH ₃	2	<i>i</i> PrOH	95%
<i>Z</i> - R = Ph	2	<i>i</i> PrOH	92%


D. Peña et al,
J. Am. Chem. Soc.,
2002, 124, 14552-3.

Unlimited. **DSM**





Cocktails anyone?

- What happens if you mix ligands?





(S)-1, R¹ = Me, R² = R³ = H
 (S)-3, R¹ = R² = Me, R³ = H
 (S)-4, R¹ = Me, R² = H, R³ = Br
 (S)-5, R¹ = Bn, R² = R³ = H



7 = 6 + 1; 8 = 6 + 2; etc.

DSM Pharma Chemicals


Unlimited. **DSM**

Combinatorial catalysis.....

- ...works! (D. Peña *et al.* *Org. Biomol. Chem.*, **2003**, 1, 1087.).
- From NMR: Almost exclusive formation of mixed complex in case of e.e. enhancement.
- Most tested combinations gave lower enantioselectivity than the homo-catalysts.
- Significantly increases the scope of asymmetric hydrogenation.
- Also shown to work with monodentate phosphites. (M. Reetz *et al.* *Angew. Chem. Int. Ed.* **2003**, 42, 790.)

DSM Pharma Chemicals

Unlimited. **DSM**



- They can all be synthesized in 1-2 steps
- Other applications besides hydrogenation: Asymmetric Heck, hydroarylation, hydrosilylation, allylic substitution.


DSM Pharma Chemicals


Unlimited. **DSM**

The combinatorial approach to ligand finding





22

- So far ligand libraries have been made manually. Each ligand synthesised and purified separately.
- Can we make ligands in a robot?
- What about purification?









Conversion




E.e.





Conversion

E.e.



Comparison

26

Ligand	Purified ligands		Library ligands	
	Conv. (%)	Ee (%)	Conv (%)	Ee (%)
NEt ₂	8	46	11	41
Piperidine	11	55	7	43
NH- α -MeBenz	96	94	51	88
NHiPr	100	95	95	92

- This HTE approach enables a very fast synthesis of a wide range of phosphoramidites and their screening in asymmetric olefin hydrogenation of
- Also less easy accessible N-H ligands can be tested.
- E.e's are slightly lower than for the conventional reaction. However, the order is representative.
- Can also be applied to other monodentate ligand families
- Can also be applied in other catalytic chemistry (C-C bond formation)


L. Lefort, J.A.F. Boogers, A.H.M. de Vries and J.G. de Vries, *Org Lett*, **2004**

DSM Pharma Chemicals


Unlimited. **DSM**

Effect of Ligand/Rh ratio

28




Rate dependence on Monophos/Rh ratio




DSM Pharma Chemicals

Unlimited. **DSM**



E.e dependence on MonoPhos/Rh ratio




DSM Pharma Chemicals

Unlimited. **DSM**


How many ligands on rhodium

- Asymmetric Amplification!
- More than 1 ligand on rhodium?




DSM Pharma Chemicals


Unlimited. **DSM**



If the “racemic” catalyst is slower than the enantiopure catalysts the e.e. will be higher than expected; positive asymmetric amplification.








If the “racemic” catalyst is faster than the enantiopure catalysts: e.e. will be lower than expected; negative asymmetric amplification.



This experiment proves the existence of RhL_2 ,
But.....

DSM Pharma Chemicals

Unlimited. **DSM**



- ..it does not rule out the existence of catalytically active RhL .

- NMR, MS and kinetic studies needed.

DSM Pharma Chemicals

Unlimited. **DSM**

Experiment with 5 mol% Rh followed over time with ES-MS (cationic mode):

After 30 min: $\text{RhL}_2(\text{nbd})$, $\text{RhL}_2(\text{Substrate})$, RhL_3 , $\text{RhL}_3(\text{Substrate})$

After 60 min: $\text{RhL}_2(\text{nbd})$, $\text{RhL}_2(\text{Substrate})$, RhL_3 , RhL_4


After 120 min: $\text{RhL}_2(\text{Substrate})$, RhL_3 , RhL_4

Conclusions:

- No RhL derived complexes found
- RhL_3 and RhL_4 cannot lead to products
- From results with mixtures of ligands: Only RhL_2 (not RhL) is an active catalyst!
- A large part of the rhodium is tied up in unproductive complexes.


^{31}P NMR

Complex made from $\text{Rh}(\text{COD})_2\text{BF}_4 + 2 \text{ MonoPhos}$; slowly added¹




$\text{Rh}(\text{MonoPhos})_2(\text{COD})\text{BF}_4$
 ^{31}P NMR in CD_2Cl_2 at various temperatures

2




^{31}P NMR $\text{Rh}(\text{MonoPhos})_2(\text{COD})\text{BF}_4$ in CD_2Cl_2 at 211K

3




complex 'a' of $\text{Rh}(\text{MonoPhos})_2(\text{COD})\text{BF}_4$ is presumed to have the following structure

4




complex 'b' of $\text{Rh}(\text{MonoPhos})_2(\text{COD})\text{BF}_4$ is presumed to have the following structure

5



- Transition metal catalysed reactions very good for:
 - Hydrogenation
 - C-C bond formation
 - Oxidation
- Enzymes are very good in:
 - Hydrolytic reactions
 - Chiral induction
 - Enormous diversity readily available in large numbers!
- Can we wed the best properties of both?
- Prior art: Whitesides and Ward (biotin linked catalysed bound to Avidin)


- Combine homogeneous catalysts that are good in hydrogenation and hydroformylation with an enzyme!
- Enzyme-Ligand-Metal
- Unfavourable weight ratio demands highly active catalyst
- Catalyst needs to be stable in aqueous environment
- Attachment at single position in enzyme for reproducibility.
- Start: Papain plus rhodium/phosphite complexes
- **Enzyme-S-linker-O-P(OR)₂Rh-(COD)BF₄**



DSM Pharma Chemicals

Unlimited. **DSM**

Selective binding of ligand to enzyme on Cys-SH





DSM Pharma Chemicals

Unlimited. **DSM**

Binding of ligand to papain is monitored by activity assay

10



DSM Pharma Chemicals


Unlimited. **DSM**

Mass Spectroscopy

11

After treatment of the ligated enzyme with $[\text{Rh}(\text{COD})_2]\text{BF}_4$ and purification only a single Rh is bound to the enzyme!

ESI-MS




DSM Pharma Chemicals

Unlimited. **DSM**

Modified enzyme is a good hydrogenation catalyst!

12



- Product N-Ac-Ala-OH is racemic
- Native papain reacted with Rh-precursor and purified in the same manner shows no reactivity.
- Next step: other enzymes and substrates.

Lavinia Panella, unpublished results

DSM Pharma Chemicals

Unlimited. **DSM**

Conclusions

13

- Monodentate phosphoramidites are excellent ligands for enantioselective olefin hydrogenation.
- Monophos is at least an order of magnitude cheaper than existing bisphosphine ligands.
- A library of 96 phosphoramidite ligands can be made in a single day and screened in catalysis the next day.
- MonophosTM and other phosphoramidites are available in research quantities via STREM
- Combination of transition metal catalysts with enzymes is a promising new field.

DSM Pharma Chemicals

Unlimited. **DSM**

DSM-Geleen

André de Vries
Jeroen Boogers
Charlotte Willans
Laurent Lefort
Sjoerd van de Wal
Math Boesten

University of Groningen

Michel vd Berg
Adri Minnaard
Ben L. Feringa
Diego Peña
Lavinia Panella
Dick Janssen
Marco Fraaije

IFOK

Detlef Heller

Financial support: DSM, University of Groningen,
Dutch Science Foundation Combichem program,
EU (RTN Network Combichem)

Hans-JG.Vries-de@dsm.com

Unlimited. DSM